Company Overview and News

 
Strong resistance for Nifty at 10,483, to find support at 10,110

2018-10-12 moneycontrol
After five weeks of massive decline, the Nifty took some breather and saw a decent pullback during the initial part of the week. However, relentless sell-off in the US markets October 10 and the following day in the Asian bourses had a rub-off effect as Nifty erased all its gain and closed significantly lower on October 11.
JBLWY 533155 JUBLFOOD

 
D-Street Buzz: Nifty auto outperforms with Ashok Leyland up 5%; HPCL jumps 4%, realty stocks gains

2018-10-12 moneycontrol
Yesterday was the day we want to forget and focus on today as the Indian stock market is witnessing some robust gains with the Nifty50 jumping 157 points, trading at 10,391 while the Sensex has zoomed over 460 points at 34,462.
IOC 500325 533096 532832 533137 DEN GAILF EICHERMOT RLNIY ASHOKLEY TVSMOTOR UNITDSPR 530965 517334 AKLD JSWSTEEL 500182 532432 TATASTEEL TATLY GAILY UQNTY AKLS IBREALEST HINDCOPPER GODREJIND 533150 500228 RELIANCE 533273 533155 JUBLFOOD 505200 532343 MOZTY 500470 RIGD JBLWY HEROMOTOCO 500477 ECQRY HINDALCO 513599 HNDNF OBZIY GODREJPROP TTST OBEROIRLTY MOTHERSUMI HRTQY ADANIPOWER 500164 500440

 
Jubilant Foodworks Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
JBLWY 533155 JUBLFOOD

 
Jubilant Foodworks Limited - Trading Window

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
JBLWY 533155 JUBLFOOD

 
Jubilant Foodworks Limited - Shareholders meeting

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
JBLWY 533155 JUBLFOOD

 
Dena Bank, Bajaj Corp, UCO Bank, MMTC, Jubilant Food top gainers among BSE Group A stocks

2018-09-18 moneycontrol
The Indian benchmark indices continues to trade in the red and have extended the earlier loses this Tuesday afternoon with the Nifty50 down 73 points and is trading at 11,304 while the Sensex is trading lower by 214 points at 37,370.
500429 GALLANTT 532726 532505 HINDUNILVR 533155 JUBLFOOD 532179 532121 CRPKY UNIPHOS JBLWY 500696 CORPBANK UCOBANK DENABANK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00B3PRM66